Key result
Cancer-associated AF research shifts toward risk stratification, targeted therapy safety, and cardiotoxicity.
Why the study?
The growing intersection between cancer and atrial fibrillation presents challenges for anticoagulation management and cardiovascular risk assessment, creating a need to characterize the global research landscape and thematic structure.
Cancer-associated atrial fibrillation research has evolved into a structured interdisciplinary subfield with increasing focus on anticoagulation management, therapy-associated arrhythmia risk, and precision-oriented care.
Answers are grounded in this paper and cite their sources.
Signals growing research momentum in cancer-associated AF; leaves open whether trends will improve clinical risk stratification or anticoagulation strategies.
BACKGROUND: Atrial fibrillation (AF) is increasingly common in patients with cancer and is associated with higher risks of stroke, bleeding, and mortality. The growing intersection between cancer and AF presents important challenges for anticoagulation management and cardiovascular risk assessment in cardio-oncology. OBJECTIVE: The purpose of this study was to systematically characterize the global research landscape, thematic structure, and developmental trajectory of cancer-AF research. METHODS: A bibliometric analysis of studies published between 1995 and 2025 was conducted using Web of Science Core Collection, PubMed, and Scopus. Web of Science Core Collection served as the primary data source for analyses of publication trends, collaboration, thematic structure, journal co-citation, and citation pathways, whereas PubMed and Scopus were used for cross-database comparison. RESULTS: Annual publication output increased markedly across all 3 databases. Research activity was concentrated in a limited number of highly productive countries, institutions, and author groups, with collaboration networks centered on major hubs. Thematic analyses identified a clinically oriented core focused on AF, cancer, stroke, anticoagulation, bleeding, and therapy-related cardiovascular risk. Temporal analyses showed a shift from early treatment-related cardiac complications toward risk stratification, targeted therapy safety, cardiotoxicity, and data-driven approaches. Journal analyses indicated sustained interdisciplinary exchange among oncology, cardiovascular medicine, and basic biomedical science. CONCLUSION: Cancer-AF research has evolved into a structured interdisciplinary subfield within cardio-oncology. This field is characterized by increasing attention to anticoagulation management, therapy-associated arrhythmia risk, and precision-oriented care. These findings provide a reference framework for future research priorities and may support more integrated cardiovascular risk assessment and management in patients with cancer.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied Cancer-associated atrial fibrillation. Bibliometric analysis of cancer-associated atrial fibrillation research from 1995 to 2025 shows a shift toward risk stratification, targeted therapy safety, cardiotoxicity, and data-driven approaches.
Synapse has enriched 10 related papers. Consider them for comparative context: